Early Loss of Glucagon Response to Hypoglycemia Found in Teens

This article originally appeared here.
Share this content:
Early Loss of Glucagon Response to Hypoglycemia Found in Teens
Early Loss of Glucagon Response to Hypoglycemia Found in Teens

(HealthDay News) – In adolescents with type 1 diabetes, the glucagon response to hypoglycemia is lost as early as one month and at a median of eight months after diabetes diagnosis, according to a study published online June 14 in Diabetes Care.

To investigate the glucagon response to hypoglycemia in adolescents with type 1 diabetes, Aris Siafarikas, MD, of the Princess Margaret Hospital for Children in Perth, Australia, and colleagues conducted a study involving 28 non-obese adolescents with type 1 diabetes (median duration, 0.66 years) and 12 healthy control subjects.

The researchers found that there was a similar glucagon peak to arginine stimulation between the groups (P=0.27). In adolescents with type 1 diabetes, the glucagon peak to hypoglycemia was statistically significantly lower than in control individuals (68 vs. 96pg/mL). For 7% of adolescents with diabetes and 83% of controls, this response was more than three standard deviations greater from baseline and was lost after a median duration of eight months of diabetes and as early as one month after diagnosis. The response did not correlate with height, weight, body mass index, or glycated hemoglobin.

"We conclude that adolescents with type 1 diabetes have impaired glucagon responses to hypoglycemia within 12 months of diagnosis," the authors write. "Prospective studies in children and adolescents starting from the onset of type 1 diabetes are needed to further characterize the mechanisms influencing the change over time in the glucagon response to hypoglycemia."

Abstract
Full Text (subscription or payment may be required)

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs